Where is sentiment landing on biotech, and where are experts most and least constructive?

Overall sentiment in the biotech industry is at its most negative in over a decade, driven by a prolonged, three-year market downturn that has created a severe capital crunch [1, 4, 7, 22]. According to the Endpoints 100 survey of executives, a record **58% rate VC investment flow as "poor,"** a stark increase from a high of 26% in previous downturn years [1, 12]. This funding drought has led to a highly selective environment where venture capital is concentrated on existing portfolio companies or a small number of top-tier new investments, making it exceptionally difficult for early-stage firms to raise capital [3, 6, 14, 15]. The financial distress is widespread, with approximately 180 public biotech companies trading for less than the value of their cash on hand [5, 6]. The pervasive pessimism is suppressing hiring, discouraging investment, and fostering a risk-averse environment that may stifle innovation, with some experts predicting the downturn has not yet reached its bottom [7, 17].

Experts are least constructive on the regulatory and political outlook, which has introduced significant anxiety and uncertainty . A new political administration's potential impact on the FDA is a primary concern, with **75% of executives** expecting the agency's reorganization to be harmful to the industry [1, 18, 20]. This perceived disorganization and lack of clarity at the FDA is viewed as a major drag on the sector that could lead to drug approval delays, deterring long-term investment [10, 11, 19]. In response to this harsh operating environment, company boards are shifting strategy, abandoning the traditional "nine lives" approach of multiple turnaround attempts . A new era of capital discipline is emerging, characterized by faster, more decisive calls to wind down underperforming assets and struggling companies when strategic alternatives fail [2, 21]. This strategic shift is compounded by a continuing R&D decoupling from China, though business development between large pharma and Chinese firms persists [9, 13, 23].

Despite the overwhelming pessimism, some experts are constructive, viewing the sector as an underappreciated and "incredibly dislocated" investment opportunity [26, 30]. This contrarian view suggests the market is overlooking significant innovation, particularly that driven by AI . While some attribute past stock rallies to macroeconomic factors like interest rate expectations , others argue that biotech-specific positive data can still drive outperformance, indicating the sector may be fundamentally undervalued . There is also tension regarding the real-world impact of political headwinds. While many express concern over populist pressure on drug pricing and reimbursement [27, 29], one analyst noted that these concerns **did not materially impact** the financial results of most companies in 2025, suggesting a potential disconnect between political rhetoric and operational reality .